acute myeloid leukemia or myelodysplastic, syndrome
Conditions
Interventions
Case series:FAB-rATG reduced intensity conditioning haplo-identical high dose non T cell depleted peripheral blood stem cell transplantation
Sponsors
First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
55 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1. Aged 55-69 years; 2. Patients with intermediate or high-risk AML and MDS: (1) Patients with initial intermediate or high-risk AML who attained CR1 by standard induction chemotherapy and MRD is undetectable; (2) Patients mentioned above who relapse for any reasons of postponing HSCT attained CR2 and MRD is undetectable; (3) Patients with initial low-risk AML failed to attain CR after 2 courses of standard induction chemotherapy. Patients who attained CR with MRD detectable, after receiving 2 courses of same or intensity chemotherapy, the MRD is undetectable; (4) Patients with initial intermediate, high-risk myelodysplastic syndrome (graded according to IPSS-R system, <=10% blasts) response after 1-2 courses of chemotherapy or do not receive any treatment; (5) Patients with very high-risk MDS (graded according to IPSS-R system, 10-20% blasts) attain CR1 or PR(<=10% blasts) after chemotherapy; (6) Patients with MDS mentioned above who progressed for postponing HSCT attain CR2 or PR (<=10% blasts); 3. Patients important organs (heart, liver, kidney, brain, etc.) do not have severe complications, and patients are suitable for transplantation by HCT-CI and EBMT transplantation scoring system evaluation; 4. Patients have HLA mismatch related donors( 5/10-9/10); 5. Patients or family members agree to conduct this research.
Exclusion criteria
Exclusion criteria: 1. Patients with AML do not attain CR or/and MRD is detectable; 2. Patients with active uncontrollable infections; 3. Patients important organs (heart, liver, kidney, brain, etc.) have severe complications, and patients are not suitable for transplantation by HCT-CI (HCT-CI>=5); 4. Patients DSA titer is over 10,000; 5. Patients with mental disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Engraft rate;Acute graft versus host disease;relapse rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-relapse mortality;Disease-free survival;Overall survival;Chronic graft versus host disease; | — |
Countries
China
Contacts
Public ContactMing Jiang
Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed